-
Mashup Score: 0Superhuman performance on urology board questions using an explainable language model enhanced with European Association of Urology guidelines - 12 hour(s) ago
Large language models encode clinical knowledge and can answer medical expert questions out-of-the-box without further training. However, this zero-shot performance is limited by outdated training data and lack of explainability impeding clinical translation. We aimed to develop a urology-specialized chatbot (UroBot) and evaluate it against state-of-the-art models as well as historical urologists’ performance in answering urological board questions in a fully clinician-verifiable manner.
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities - 8 day(s) ago
Clinical trials (CTs) play a crucial role in advancing new oncology therapies and their eventual integration into cancer care. However, despite the increasing number of available CTs, <5% of patients with cancer are included.1 The biggest challenge in getting patients with cancer to participate in CTs is the lack of available trials at the hospital where the patient is being treated, due to the heterogeneous distribution of CTs.2 Other key factors that significantly influence patient recruitment for CTs and still require substantial attention are significant social disparities and certain structural issues within health care systems, such as incompatibilities between public and private systems within the same country.
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Avelumab first-line (1L) maintenance is recommended as the standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression following 1L platinum-based chemotherapy (PBC). We report results from READY, a real-world study of avelumab 1L maintenance in an Italian compassionate use program (CUP).
Source: www.esmorwd.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 60Home Page: ESMO Real World Data and Digital Oncology - 13 day(s) ago
ESMO Real-World Data and Digital Oncology is the European Society for Medical Oncology’s latest peer-reviewed open access journal. It is dedicated to publishing high-quality data science and educational content on the transformation of oncology care with real-world evidence and digital technologies that physicians can trust and understand. The journal will publish innovative research that provides actionable insights from real-world data sources and digital devices, such as generalizable observational
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 37Clinical trial and real-world evidence of circulating tumor DNA monitoring to predict recurrence in patients with resected colorectal cancer - 20 day(s) ago
Circulating tumor DNA (ctDNA) is a novel biomarker to predict recurrence in colorectal cancer (CRC). However, clinical validation data in underrepresented patient populations like Southeast Asians are lacking.
Source: www.esmorwd.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers - 1 month(s) ago
BRAF V600 mutations are the epitome of targeted therapy. However, not much is known about non-V600 mutations. Using the new data infrastructure of the Swiss Personalized Oncology project of the Swiss Personalized Health Network (SPHN), we evaluated the fate of patients with cancer with non-V600 BRAF mutations in comparison to patients with class 1 mutations.
Source: www.esmorwd.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Adoption of electronic patient-reported outcomes in cancer clinical practice: the point of view of Italian patients - 1 month(s) ago
In 2022, the European Society for Medical Oncology (ESMO) guideline recommended the adoption of electronic patient-reported outcomes measures (ePROMs) in routine clinical practice for patients with cancer. The aim of this survey is to identify the critical issues that would arise in the implementation of ePROMs in daily oncology clinical practice from patients’ view.
Source: www.esmorwd.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Using real world data to bridge the evidence gap left by prostate cancer screening trials - 1 month(s) ago
Population-based prostate cancer screening is currently not recommended in the UK because harms may outweigh benefits. Recent changes to the diagnostic pathway have improved safety and accuracy, but uncertainty remains as to how much they have shifted the screening harm to benefit ratio. Our work uses modelling and real-world data (RWD) to bridge this evidence gap.
Source: www.esmorwd.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
Dual blockade therapy encorafenib–cetuximab (EC) was recently established as the standard of care for second- or third-line treatment for BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients based on BEACON phase III study results. The CONFIDENCE study aims to provide insight about the real-world (RW) safety and effectiveness of EC in a Spanish cohort.
Source: www.esmorwd.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Digital twins: a new paradigm in oncology in the era of big data - 3 month(s) ago
Recent advancements in health care digitalization opened the collection and availability of big data, whose analysis requires artificial intelligence-based technologies to facilitate the development of predictive tools supporting decision making in clinical practice. In this context, the idea of constructing ‘digital worlds’ to evaluate the performance of such novel tools becomes more attractive. Digital twins (DTs) are ‘digital objects’ characterized by a bi-directional interaction with their ‘real-world counterparts’.
Source: www.esmorwd.orgCategories: General Medicine News, Oncologists1Tweet
New research in @myEsmo ESMO Real World Data and Digital Oncology shows explainable AI achieving 88% accuracy and superhuman performance in answering medical questions. https://t.co/KFOr6NC4NJ https://t.co/HcuvlcP7il